These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29703155)

  • 21. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.
    Taye S; Lakew M
    BMC Immunol; 2013 May; 14():23. PubMed ID: 23679118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with therapeutic success in HIV-positive individuals in southern Brazil.
    Silveira MP; Maurer P; Guttier MC; Moreira LB
    J Clin Pharm Ther; 2015 Apr; 40(2):192-5. PubMed ID: 25422132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of virological failure among adults on first-line highly active antiretroviral therapy at public health facilities in Kombolcha town, Northeast, Ethiopia: a case-control study.
    Meshesha HM; Nigussie ZM; Asrat A; Mulatu K
    BMJ Open; 2020 Jul; 10(7):e036223. PubMed ID: 32713849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time to initial highly active antiretroviral therapy discontinuation and its predictors among HIV patients in Felege Hiwot comprehensive specialized hospital: a retrospective cohort study.
    Amera TG; Bogale KA; Tefera YM
    AIDS Res Ther; 2021 Dec; 18(1):93. PubMed ID: 34863200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological Response of Hiv-Infected Children to Highly Active Antiretoviral Therapy at Gondar University Hospital, North-Western Ethiopia.
    Kokeb M; Degu G
    Ethiop J Health Sci; 2016 Jan; 26(1):25-30. PubMed ID: 26949313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.
    Kober C; Johnson M; Fisher M; Hill T; Anderson J; Bansi L; Gompels M; Palfreeman A; Dunn D; Gazzard B; Gilson R; Post F; Phillips AN; Walsh J; Orkin C; Delpech V; Ainsworth J; Leen C; Sabin CA;
    HIV Med; 2012 Jan; 13(1):73-8. PubMed ID: 22106827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Socio-Demographic, Economic and Clinical Predictors for HAART Adherence Competence in HIV-Positive Adults at Felege Hiwot Teaching and Specialized Hospital, North West Ethiopia.
    Tegegne AS
    HIV AIDS (Auckl); 2021; 13():749-758. PubMed ID: 34267557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of change in CD4 lymphocyte count and weight among HIV infected patients on anti-retroviral treatment in Ethiopia: a retrospective longitudinal study.
    Reda AA; Biadgilign S; Deribew A; Gebre B; Deribe K
    PLoS One; 2013; 8(4):e58595. PubMed ID: 23573191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru.
    López de Castilla D; Verdonck K; Otero L; Iglesias D; Echevarría J; Lut L; Gotuzzo E; Seas C
    Int J Infect Dis; 2008 May; 12(3):325-31. PubMed ID: 18546542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study.
    Asfaw A; Ali D; Eticha T; Alemayehu A; Alemayehu M; Kindeya F
    PLoS One; 2015; 10(3):e0122583. PubMed ID: 25816222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients who restart antiretroviral medication after interruption remain at high risk of unfavorable outcomes in Ethiopia.
    Teklu AM; Yirdaw KD
    BMC Health Serv Res; 2017 Apr; 17(1):247. PubMed ID: 28376805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of longitudinal changes of CD4 cell count and survival time to death of HIV/AIDS patients treated at Yabelo General Hospital, the case of pastoralist area: Using joint modelling approach.
    Nura GJ; Guyo AB; Erango MA
    PLoS One; 2024; 19(6):e0305519. PubMed ID: 38913649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological and virological discordance among people living with HIV on highly active antiretroviral therapy in Tigray, Northern Ethiopia.
    Hailu GG; Wasihun AG
    BMC Infect Dis; 2021 Jun; 21(1):561. PubMed ID: 34118891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with immunological and virological discordant responses to highly active antiretroviral therapy among adult HIV positive individuals in Ethiopia: A cross-sectional study.
    Manaye GA; Abateneh DD; Asmare WN; Abebe M
    Medicine (Baltimore); 2021 Nov; 100(47):e27624. PubMed ID: 34964727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.